Stock Price
12.54
Daily Change
0.44 3.64%
Monthly
40.11%
Yearly
47.53%
Q4 Forecast
11.63

EPS Reference Time Actual Consensus Previous
2026-10-28 FY2026Q3 PM 1.77 1.28 1.16
2026-07-29 FY2026Q2 PM 1.26 1.03 1.05
2026-04-29 FY2026Q1 PM 0.78 0.71 0.61
2026-02-18 FY2025Q4 PM 1.08 1.25 1.14
2025-10-29 FY2025Q3 PM 1.16 1.1 1.14



Peers Price Chg Day Year Date
Aurora Cannabis 6.53 0.06 0.93% 4.98% Nov/18
Amgen 446.52 -11.41 -2.49% 30.41% Nov/18
ANI Pharmaceuticals 71.65 1.66 2.37% -11.62% Nov/18
Biogen 251.64 0.85 0.34% 49.05% Nov/18
Bristol-Myers Squibb 60.05 -1.30 -2.12% 31.14% Nov/18
Corcept Therapeutics 68.61 -1.46 -2.08% -8.65% Nov/18
Danaher 228.05 2.28 1.01% 2.54% Nov/18
Gilead Sciences 169.42 -0.84 -0.49% 32.29% Nov/18
Eli Lilly 1,392.00 -23.55 -1.66% 32.62% Nov/18
Nektar Therapeutics 35.02 -0.89 -2.48% -40.81% Nov/18

Indexes Price Day Year Date
TSX 34664 -651.43 -1.84% 14.48% Nov/18
Canada TSX 60 Index 2068 -34.96 -1.66% 16.05% Nov/18

Bausch Health Companies Inc traded at 12.35 this Wednesday November 18th, increasing 0.25 or 2.07 percent since the previous trading session. Looking back, over the last four weeks, Bausch Health Companies gained 37.99 percent. Over the last 12 months, its price rose by 45.29 percent. Looking ahead, we forecast Bausch Health Companies Inc to be priced at 11.63 by the end of this quarter and at 10.85 in one year, according to Trading Economics global macro models projections and analysts expectations.

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.